Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 4 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 84Breast Neoplasms 10Neoplasm Metastasis 7Neoplasms 5Prostatic Neoplasms, Castration-Resistant 4Prostate Cancer Metastatic 4Metastatic Castration-Resistant Prostate Cancer 4Metastatic Castration-resistant Prostate Cancer 3Castration-resistant Prostate Cancer 3Triple Negative Breast Neoplasms 2Castration Resistant Metastatic Prostate Cancer 2Adenocarcinoma of the Prostate 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Prostate Adenocarcinoma 1Primary Breast Cancer ER+ve 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Non-metastatic, Hormone naïve Prostate Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Progressive Castration-resistant Prostate Cancer 1Metastatic Hormone-sensitive Prostate Cancer 1

Interventions

enzalutamide 4cabazitaxel 3Docetaxel 3Prednisone 2talazoparib 1rucaparib 1pembrolizumab 1olaparib 1Zuclomiphene 1XRP6258 1Standard of Care 1Radiosurgery 1Positron Emission Tomography Computed Tomography 1LY3023414 1Injections 1Carboplatin 1Abituzumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Prostate Cancer Metastatic × enzalutamide × Clear all
NCT02814968 2022-04-14

PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide

The European Uro-Oncology Group

Phase 2 Completed
66 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT02815033 2022-04-14

Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

The European Uro-Oncology Group

Phase 2 Completed
66 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT02407054 2021-05-11

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Eli Lilly and Company

Phase 2 Completed
142 enrolled 16 charts
Genitourinary

Prostate Cancer Metastatic

NCT02379390 2019-06-21

PRIMCAB

Sanofi

Phase 2 Terminated
8 enrolled 8 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡